PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis

Chengcheng Hao1†, Gang Chen2†, Huishan Zhao3, Yan Li1†, Jianxin Chen1, Hongmei Zhang1†, Shan Li1†, Yuze Zhao1†, Feng Chen4, Wenbin Li4* and Wen G. Jiang5*

1 Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China, 2 Beijing Qinglian Biotech, Co., Ltd., Beijing, China, 3 Reproductive Medicine Centre, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China, 4 Department of Neuro-Oncology, Neurosurgery Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 5 Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, United Kingdom

Background: The clinical and prognostic value of programmed death-ligand 1, PD-L1, in glioblastoma remains controversial. The present study aimed to identify the expression of PD-L1 for its prognostic value in glioblastoma.

Methods: A comprehensive literature search was performed using the PubMed and CNKI databases. The overall survival (OS) and disease-free survival (DFS) of GBM was analyzed based on Hazard ratios (HRs) and 95% confidence intervals (CIs). Furthermore, Odds ratios (ORs) and 95% CIs were summarized for clinicopathological parameters. The statistical analysis was using RevMan 5.3 software.

Results: The meta-analysis was performed by using total nine studies including 806 patients who had glioblastoma. The pooled results indicated that PD-L1 expression in tumor tissues was significantly related to a poor OS (HR = 1.63, 95%CI: 1.19–2.24, P = 0.003, random effects model) with heterogeneity (I² = 51%). In subgroup analyses, PD-L1 positivity was significantly associated with a worse OS for patients of American and Asian regions, but not for those of European regions. Moreover, PD-L1 expression implied a trend toward the mutation status of the IDH1 gene [coding the Isocitrate Dehydrogenase (NADP(+))-1 protein] (HR = 9.92, 95%CI: 1.85–53.08, P = 0.007, fixed effects model). However, the prediction overall survival (OS) of the patients showed that PD-L1 expression was independent from other clinicopathological features, such as gender and age.

Conclusions: Our analyses indicated that high expression of PD-L1 in glioblastoma tumor tissues is associated with poor survival of patients, and PD-L1 may act as a prognostic predictor and an effective therapeutic target for glioblastoma.

Keywords: glioblastoma, PD-L1, prognostic, clinicopathological, meta-analysis
INTRODUCTION

Glioblastoma represents the most commonly seen primary malignant brain tumor in adults, characterized by high aggressive behavior and high recurrence rate (1). Multimodality therapies have been suggested and practiced according to NCCN Guidelines, including surgical resection, radiotherapy with alkylating agents such as temozolomide (TMZ) and adjuvant TMZ chemotherapy. However, the outcomes of the treatment are far from satisfactory with the 5-year overall survival being <10% (2–4).

Differently from many other tumors, molecularly targeted therapies for glioblastoma produced very limited advances in prolonging life expectancies of the patients, reasons at least partly attributable to the poor penetration of the Blood Brain Barrier (BBB) by therapeutic agents or by rapidly developing drug resistance (5, 6). In the recent years, it is increasingly recognized that the central nervous system (CNS) interacting actively with the systemic immune system have offered a new exciting theoretical basis and promising opportunities for brain tumor immunotherapy (7–10).

Tumor cells can display immune evasion to weaken antitumor immunity by activating the so-called immune Checkpoint molecules (ICs) (11). Programmed cell death ligand-1 (PD-L1), a “classic” IC molecule, has the effect on induction of T-cell-mediated immune tolerance in tumor local microenvironment, leading to tumor immune escape and tumor growth stimulation, by combination with programmed cell death-1 (PD-1) located on the surface of activated T cells (12). PD-L1 has been shown to be upregulated in various cancer cells and associated with unfavorable prognosis (13–18). Over the past decade, immunotherapies targeting PD-L1/PD-L1 axis have made a series of remarkable breakthroughs in prognosis improvement of hard-to-treat solid tumors (including head and neck squamous cell carcinoma, non-small cell lung cancer, gastric cancer, urethelial cancer, cervical cancer, and melanoma) and have entered in the standard clinical practice (19–24). Recently, the expression of PD-L1 on glioma cells has been documented (25, 26). Researches have increasingly concerned over the prognostic evaluation of PD-L1 in patients with glioblastoma. However, whether PD-L1 expression correlates with prognosis in glioblastoma patients remains controversial. Therefore, we assessed the consistency and magnitude of the prognostic and clinical significance of PD-L1 in glioblastoma patients through a systematic review and meta-analysis.

MATERIALS AND METHODS

Literature Search Strategy

The implementation of this systematic review and meta-analysis followed the guideline of PRISM, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. We systematically reviewed the literature published in the PubMed and CNKI (China National Knowledge Infrastructure) databases (dated to July 2019). The following key words were adopted: (“glioblastoma” OR “GBM” OR “glioma” OR “brain tumor” OR “brain cancer” OR “cerebral tumor” OR “intracranial tumor”) AND (“CD 274” OR “PD-L1” OR “Programmed Cell Death 1 Ligand 1”) without restrictions on languages, regions and publication types.

Inclusion and Exclusion Criteria

The study adopted the following inclusion criteria: (1) All patients were diagnosed with glioblastoma by histological examination; (2) Hazard ratio (HR) and 95% confidence intervals (CIs) could be available; or the association between PD-L1 and overall survival (OS) or disease-free survival (DFS) with sufficient data were provided.

The study excluded the following: (1) conference abstracts, case reports, reviews, basic research, clinical trials; (2) studies missing available data.

Data Extraction and Quality Assessment

Two investigators independently reviewed potentially relevant studies in order to minimize bias. A third reviewer was brought in when there were disagreements. We extracted the following data from the included studies: authors, name of the journal, year of publication and ethnicity, number of enrolled patients, tumor histology, PD-L1 expression level, cut off value, detection area, detection methods, and follow-up.

If only survival curves were available, the data could be extracted from the Kaplan Meier curves. The quality of each retrieved article was assessed independently by two assessors according to the Newcastle-Ottawa Quality Assessment Scale (NOS). A total score of 0–9 was assigned to each included study, and studies with a NOS score≥5 were considered to be of high quality (27).

Statistical Analysis

The association between PD-L1 expression with OS and DFS of patients with glioblastoma was evaluated according to the HR and 95% CI. Statistical heterogeneity among studies was quantified with the Cochran’s Q test and the I² statistic. We used a random-effects model to pool the data when evidence suggested significant heterogeneity (I²>50% or P < 0.1), while a fixed-effects model was conducted otherwise. Subgroup analyses and sensitivity analyses were attempted to explain the origin of heterogeneities. The potential publication bias was estimated by the Begg’s and Egger’s tests with significance of P < 0.05. Review Manager Version 5.3 (Cochrane Collaboration, Oxford, UK) and STATA 15 were statistical packages used in the study.

RESULTS

Characteristics of Included Studies

A total of 201 potentially relevant records were obtained according to the search strategy mentioned above. One hundred and eighty-eight studies were rejected after screening the titles and abstracts. Thirteen studies were included for further evaluation, of which 4 articles without eligible survival data were excluded. Finally, nine studies with 806 patients fulfilled the criteria and entered the meta-analysis. The selection flowchart
and the baseline information of the studies are, respectively, displayed in Figure 1 and Table 1.

**Association Between PD-L1 Expression and Prognostic Parameters**

**PD-L1 Expression and the Overall Survival (OS) of the Patients**

Nine studies presented OS data (n = 806). Significant heterogeneity existed amongst studies included in the analyses (I² = 51%, P = 0.04). Pooled result by a random-effects model revealed a significantly inverse correlation between PD-L1 overexpression and OS of patients with glioblastoma (HR = 1.63, 95% CI: 1.19–2.24, P = 0.003) (Figure 2).

**PD-L1 Expression and Association With the Diseases Free Survival (DFS)**

As shown in Figure 3, three studies (n = 299) focused on DFS and no heterogeneity was existed amongst the studies (I² = 10%, P = 0.33). However, pooled analysis by fixed model did not reveal any significant link between PD-L1 and DFS of patients (HR = 0.82, 95% CI: 0.58–1.15, P = 0.25).

**PD-L1 Expression and Clinicopathological Characteristics**

**Age**

Two studies, consisting of 246 patients, assessed the correlation between age and PD-L1 expression. As shown in Figure 4A, 90 (51.14%) of 176 younger patients (whose age defined as younger than 50 yrs) showed PD-L1 expression, compared with 57.14% (40 of 70) of older patients (≥ 50 years of age) who had PD-L1 overexpression. PD-L1 expression did not correlate significantly with age (OR = 0.92, 95% CI: 0.51–1.65, P = 0.78).

**Gender**

The dependability between PD-L1 expression and gender was assessed in three studies involving 300 patients. Eighty-five (52.47%) of 162 male patients and 64 (46.38%) of 138 female patients were PD-L1 overexpression. The results indicated that PD-L1 overexpression had no significant association with gender (OR = 1.20, 95% CI: 0.75–1.92, P = 0.44; Figure 4B).

**Ethnicity**

In ethnicity subgroup, the stratified analysis revealed PD-L1 positivity was linked to unfavorable OS in patients...
### TABLE 1 | General characteristics of included studies.

| References | Journal | Year | Country | No. of patients | Treatment | Methods | Cut-off point (high/low) | HR estimation | Quality assessment |
|------------|---------|------|---------|----------------|-----------|---------|--------------------------|---------------|-------------------|
| 1 Liu et al. (28) | The Journal of Neuroscience | 2013 | Denmark | 17 | Surgery | IFC | 10–100 positive cells | OS | 6 |
| 2 Berghoff et al. (25) | Neuro-Oncology | 2015 | Austria | 135 | Surgery | IHC | 5% of positive cells | OS | 7 |
| 3 Nduom et al. (29) | Neuro-Oncology | 2016 | USA | 94 | Surgery | IHC | 5% of positive cells | OS | 7 |
| 4 Zeng et al. (30) | Oncotarget | 2016 | China | 229 | Surgery | IHC | 5% of positive cells | OS +DFS | 8 |
| 5 Han et al. (31) | Journal of Pathology and Translational Medicine | 2017 | Korea | 54 | Surgery | IHC | 5% of positive cells | OS +DFS | 8 |
| 6 Miyazaki et al. (32) | Journal of Neuro-Oncology | 2017 | Japan | 16 | Surgery | IHC | 50% of positive cells | OS +DFS | 7 |
| 7 Lee et al. (33) | Journal of Neuro-Oncology | 2017 | Korea | 115 | Surgery | IHC | 5% of positive cells | OS | 7 |
| 8 Pratt et al. (34) | Neurosurgery | 2018 | USA | 125 | Surgery | IHC | 5% of positive cells | OS | 8 |
| 9 Hwang et al. (35) | Journal of Neuro-Oncology | 2018 | South Korea | 21 | Surgery | IHC | Score ≥2 (infrequent small clusters of positive cells) | OS | 7 |

**FIGURE 2** | Forest plot of 9 studies evaluating the association between PD-L1 expression and OS in glioblastoma patients.

**FIGURE 3** | Forest plot of 3 studies evaluating the association between PD-L1 expression and DFS in glioblastoma patients.

from the Asian regions (five studies with 435 cases: HR = 3.01, 95%CI:1.21–7.48, \(P = 0.02\)) and the American regions (two studies with 219 cases: HR = 2.09, 95% CI:1.48–2.94, \(P < 0.0001\)), but not in patients from the European studies (two studies with 152 cases: HR = 1.78, 95% CI:0.55–5.81, \(P = 0.34\) (Figure 5).
IDH1 [Isocitrate Dehydrogenase (NADP(+))-1 Coding Gene] Status

Two separate studies, encompassing 209 patients in total, evaluated a possible connection between IDH1 mutation (namely IDH1-wild type vs. with IDH1 mutation) and PD-L1. Of the 183 tumors which displayed IDH1-wild type, 67 (36.61%) were PD-L1 positive. Of the 26 tumors which had IDH1-mutation, one (3.85%) was PD-L1 positive expression.
The pooled OR indicated that PD-L1 positivity was closely related to IDH1 status (OR = 9.92, 95% CI: 1.85–53.08, P = 0.007) (Figure 6).

In a subgroup analysis using a random effects model, heterogeneity was revealed in relation to PD-L1 and ethnicity of the patients (P < 0.00001, I² = 91%).

Sensitivity Analysis and Publication Bias
Finally, we found no significant publication bias in the nine studies entered the current analysis, by, respectively, applying the Begg’s test and the Egger’s test (P = 0.917 and P = 0.527, respectively) (Figure 7).

DISCUSSION
PD-L1 is a coinhibitory ligand expressed in many types of tumor cells. It has been indicated that the binding of PD-L1 to its receptor PD-1 induces T cell dysfunction and apoptosis which plays a crucial role in tumor immune evasion. Gliomas have been recognized as an immunosuppressive tumor. The current understanding to glioma-mediated immunosuppression have generated increasing interest in the correlations between PD-L1 expression and survival for gliomas, particularly glioblastomas. However, the published results about glioblastomas remain controversial. In 2013 Liu et al. first reported that the expression of PD-L1 in seventeen patients with glioblastoma is a possible indicator for poor clinical outcome (28). Using level 3 Illumina RNASeq, Nduom et al. also found PD-L1 overexpression was indicative for shorter survival time in 149 patients with glioblastoma from (data from the Cancer Genome Atlas (TCGA) dataset) (29). Various other studies showed similar results (31, 33, 34). However, in a retrospective study of 117 newly diagnosed glioblastomas as well as a TCGA database analysis comprising 446 glioblastoma patients, researchers did not find a significant connection between PD-L1 and the OS (25). The similar views were also taken in several other analyses (30, 32). To clarify a reasonable evidence-based conclusion, a meta-analysis including 9 studies with a total of 806 patients was performed. The present meta-analysis showed that PD-L1 positive expression was significantly associated with poor OS (HR = 1.63, 95% CI: 1.19–2.24, P = 0.003) in glioblastoma patients after surgery; however, there were insufficient evidence to suggest that PD-L1 was related to DFS (HR = 0.82, 95% CI: 0.58–1.15, P = 0.25). These results suggested that PD-L1 positive expression might be a negative prognostic factor in glioblastomas.

To further explore the potential sources of heterogeneity in the relationship between PD-L1 and overall survival in glioblastoma, we utilized subgroup analyses. The results confirmed that the significance of PD-L1 in OS was not affected by gender and age, collectively suggesting that this relationship is independent of these factors in tumor type. The influence of PD-L1 on the OS of multiethnic patients was also explored. Patients were classified as from Asia, America and Europe. Different combined HRs
and P-values for OS were shown in different ethnic groups: PD-L1 overexpression was significantly associated with poor OS for patients from Asia and America, while no significant association for the survival of patients from Europe survival, which suggested that racial differences may be a potential origin of heterogeneity in glioblastoma. This “ethnic biasedness” of PD-L1 has been observed in several clinical studies for patients with certain other types of solid tumors. KEYNOTE-181, a phase 3 trial of Pembrolizumab (P) vs. chemotherapy (paclitaxel, docetaxel or irinotecan) in patients with esophageal squamous cell carcinoma, showed that P was superior to chemotherapy for OS in patients with PD-L1 positive expression (CPS≥10) in the global cohort, especially in the Chinese subgroup (36). Similarly, in the KEYNOTE-062 (a study of Pembrolizumab vs. chemotherapy in patients who had advanced gastric or gastro-esophageal junction cancer), P didn’t bring significant survival benefits as the first-line treatment for PD-L1-positive (CPS≥1) population in the full global cohort (37). However, in further ethnicity subgroup analysis, P showed lower risk of death in Asians with PD-L1 positive expression (CPS≥1) when compared to chemotherapy, but not in Europeans, Americans and Australians. The findings in stratified analyses revealed that PD-L1 holding a prognostic role in different ethnic groups may have potential implications immunotherapeutics and prognostication for stratify patients. It is possible that the immunogenetics might to some extent differ in different races (38). So the subgroup analysis stratified by ethnicity may be necessary for accurately assessing the potential prognostic value of PD-L1 and the efficacy of relevant immunotherapy drugs in further clinical studies for glioblastoma.

According to the updated 2016 World Health Organization (WHO) classification of diffuse gliomas, Isocitrate dehydrogenase (IDH) has been considered as one of the important molecular biomarkers that has diagnostic, prognostic and predictive application (39–42). Studies have reported that glioblastomas which are hotspot mutation in IDH1 (an isomform of IDH) generally have a significantly better prognosis compared with IDH1-wildtype glioblastomas (43–45). Moreover, the expression of PD-L1 in diffuse gliomas might be directly influenced by IDH1 mutational status (33, 46, 47). Therefore, the relation between PD-L1 expression and IDH1 status was further investigated in the stratified analysis. We found that IDH1-wildtype status in glioblastoma was PD-L1 expression positive. The result confirmed recent findings of a PD-L1/IDH1-wildtype association. The hypothesis about its mechanism of this connection was that IDH1 mutation can result in the PD-L1 promoter hypermethylation that downregulates the expression of PD-L1 (48, 49). So the PD-L1 immune checkpoint inhibitors might not be advisable because of the low PD-L1 expression in patients with IDH1-mutant glioblastomas.

Recent research has showed that tumor cells in gliomas can regulate PD-L1 expression via two major mechanisms to mediate immune evasion, “adaptive resistance” mechanism and “innate resistance” mechanism (50). The former is for extrinsic induction of PD-L1. IFN-γ, a proinflammatory cytokine primarily produced by tumor infiltrating lymphocytes (TILs), can induce PD-L1 upregulation via NF-κB/PKD2 signal pathway (51–53). The latter is proved to mediate intrinsic induction of PD-L1. When there is a lack of TILs, PD-L1 induction in glioma cells might depend on multiple oncoenic signaling pathways (such as JAK/STAT 3, PI3K/Akt/mTOR/S6K1 and EGFR/MAPK pathway) or oncogene mutations (such as ALK, EGFR and PTEN) (11, 54–60).

It has been indicated that PD-L1 may be a valuable therapeutic target in cancer immunotherapy (9, 61). Recently, promising preclinical data in murine models of glioma have provided support for PD-L1 checkpoint inhibitors implementation in GBM patients (62–64). However, early clinical trials on the effectiveness of PD-L1 blockade agents are still limited and elusive. A combination between Anti-PD-L1 mAb durvalumab and bevacizumab is now being tested in a phase 2 open label, non-randomized clinical trial for GBM (cohort B, NCT02336165) (65). Interim results of durvalumab monotherapy revealed low SAE (severe adverse events) rate of 10% and efficacy with OS-6 of 42% and PFS-6 (progression-free survival) of 20%. Trials for other cohorts (cohort A: newly diagnosed MGMT-promoter unmethylated GBM, cohort C: refractory recurrent GBM) are still ongoing. Atezolizumab, a humanized antibody to PD-L1 that has been approved for second-line treatment for patients with advanced or metastatic NSCLC (non-small cell lung cancer) and urothelial cancer, is also being studied in a phase 1a clinical trial for multiple solid tumors, including GBM (PCD4989g: NCT01375842) (66). Results showed that Atezolizumab was safe and well-tolerated in patients with GBM. Glioblastoma was considered a type of “immunologically cold tumor” due to the relative lack of tumor infiltrating T cells in the tumor micro-environment (TME) and high selectivity of BBB (67–69). The “cold” phenotype of GBM may limit immunotherapy efficacy. Combinatorial treatment approaches targeting immune-suppression or BBB permeability may help shift the “cold” microenvironment and enhance response to immune checkpoint blockade in GBM, including radiation therapy, chemotherapy, other immunotherapies (e.g., Chimeric antigen receptor T-cells, oncolytic virus), and bevacizumab (70, 71).

So far as we are aware, the present study is the first meta-analysis to systematically estimate the correlation between PD-L1 and clinical outcomes and clinicopathological factors in glioblastoma. While some limitations need attention. Firstly, different analysis strategy of IHC and inconsistent cut-off values of PD-L1 expression may lead to heterogeneity between studies. Thus, a standardized approach for protein expression should be set up to improve consistency and veracity in the measurement of PD-L1 for future studies. Secondly, some subgroups, such as the IDH1 status group, had small sample sizes. Thirdly, the investigation about the correlations between PD-L1 and clinical features, including as tumor size, tumor site and surgical approach are not performed due to the deficiency of related original information.

In conclusion, our meta-analysis shows that high PD-L1 expression is strongly correlated with unfavorable prognosis for GBM patients. PD-L1 may present itself as a valuable target...
for immunotherapy in clinical practice. Additional high-quality, larger-scale prospective studies are needed to provide validated the potential value of PD-L1 for the prognosis and treatment of GBM patients in the future.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

REFERENCES

1. Aliferis C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. (2015) 152:63–82. doi: 10.1016/j.pharmthera.2015.05.005

2. Komorat RJ, Otten ML, Moise G, Connolly ES Jr. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma—a critical review. Clin Med Oncol. (2008) 2:421–2. doi: 10.4137/CMO.S390

3. Afroniti ML, Heery CR, Herndon JE II, Rich JN, Reardon DA, Desjardins A, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multagent chemotherapy. Cancer. (2009) 115:5301–11. doi: 10.1002/cncr.24398

4. Ostrom QT, Gittleman H, Fulp J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. (2015) 17 (Suppl. 4):e1–62. doi: 10.1093/neuonc/nov189

5. Schlager KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res. (1999) 58:312–28. doi: 10.1006/mvre.1999.2188

6. Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals. (2013) 6:1475–506. doi: 10.3390/ph6121475

7. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. (2011) 17:1603–15. doi: 10.1158/1078-0432.CCR-10-2563

8. Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumours: no longer a matter of privilege. Clin Cancer Res. (2014) 20:5620–9. doi: 10.1158/1078-0432.CCR-14-0832

9. Garber ST, Hashimoto Y, Weathers SP, Xu Ji, Gatalica Z, Verhaak RG, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. (2016) 18:1356–67. doi: 10.1093/neuonc/now132

10. Cloughesy TF, Mochizuki YA, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. (2019) 25:477–86. doi: 10.1038/s41591-018-0337-7

11. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a topolamian dendritic approach to cancer therapy. Cancer Cell. (2015) 27:450–61. doi: 10.1016/j.ccell.2015.03.001

12. Wei E, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA. (2013) 110:E2480–9. doi: 10.1073/pnas.1305394110

13. Thompson RH, Kunz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. (2006) 66:3381–5. doi: 10.1158/0008-5472.CAN-05-4303

14. Nakashima J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. (2007) 56:1173–82. doi: 10.1007/s00262-006-0266-z

15. Chen XL, Yuan SX, Chen C, Mao YX, Xu G, Wang XY. [Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance]. Ai Zheng. (2009) 28:1328–32. doi: 10.5732/cjc.09.10245

16. Wu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. (2011) 28:682–8. doi: 10.1007/s12033-010-9515-2

17. Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. (2015) 9:901–9. doi: 10.2147/DDDT.S75152

18. Enkhbat T, Nishi M, Takasu C, Yoshikawa K, Jun H, Tokunaga T, et al. Programmed cell death ligand 1 expression is an independent prognostic factor in colorectal cancer. Anticancer Res. (2018) 38:3367–73. doi: 10.21873/anticancer.12603

19. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death ligand 1 (PD-1) in gastric carcinoma and its clinical significance. Acta Histochem. (2006) 108:19–24. doi: 10.1016/j.acthis.2006.01.003

20. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumour PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. (2014) 20:2773–82. doi: 10.1158/1078-0432.CCR-14-1880

21. Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther. (2015) 15:981–93. doi: 10.1586/14737442.2015.1074862

22. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. (2016) 375:1823–33. doi: 10.1056/NEJMoa1606774

23. Zhu Q, Cai MY, Chen CL, Hu H, Lin HX, Li M, et al. Tumour cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumour-infiltrating lymphocytes. OncoImmunology. (2017) 6:e1312240. doi: 10.1080/2162402X.2017.1312240

24. Rotte A, D’orazi G, Bhandaru M. Nobel committee honors tumour immunologists. J Exp Clin Cancer Res. (2018) 37:262. doi: 10.1186/s13046-018-0937-6

25. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. PD-L1 expression by neurons nearby tumours indicates better immune infiltrates associated with improved clinical outcome in patients with non-small-cell lung cancer. Neuro Oncol. (2017) 19:1064–75. doi: 10.1093/neuonc/nou307

AUTHOR CONTRIBUTIONS

CH and GC designed this study, searched the literature, screened identified studies and extracted data, and wrote the manuscript. Disagreements were resolved by discussion with WJ and WL. HZhang, FC, YL, SL, HZhang, YZ, and JC assisted in the literature search and screening. WJ and WL assisted in the designing of the study and the data analyses, and supervised the study. All authors have read and approved the final version of this manuscript.

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. (2016) 18:195–205. doi: 10.1093/neuonc/nov172
30. Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget. (2016) 7:8944–55. doi: 10.18632/oncotarget.6884

31. Han J, Hong Y, Lee YS. PD-L1 expression and combined status of PD-L1/PD-1-positive tumour infiltrating mononuclear cell density predict prognosis in glioblastoma patients. J Pathol Transl Med. (2017) 51:40–8. doi: 10.4132/jptm.2016.08.31

32. Miyazaki T, Ishikawa E, Matsuda M, Akutsu H, Osuka S, Sakamoto N, et al. Assessment of PD-1 positive cells on initial and secondary resected tumour specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol. (2017) 133:277–85. doi: 10.1007/s11060-017-2451-7

33. Lee KS, Lee K, Yun S, Moon S, Park Y, Han JH, et al. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. J Neurooncol. (2018) 136:453–61. doi: 10.1007/s11060-017-2675-3

34. Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, et al. Programmed cell death ligand 1 is a negative prognostic marker in recurrent isocitrate dehydrogenase-wildtype glioblastoma. Neurosurgery. (2019) 85:280–9. doi: 10.1093/neuros/ney268

35. Hwang K, Koh EI, Choi EI, Kang TH, Han JH, Choe G, et al. PD-1/PD-1L and immune-related gene expression pattern in pediatric malignant brain tumours: clinical correlation with survival data in Korean population. J Neurooncol. (2018) 139:281–91. doi: 10.1007/s11060-018-2886-5

36. Chen J, Luo S, Qin S, Cheng Y, Li Z, Fan Y, et al. Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenosquamous carcinoma (ac) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: analysis of the chinese subgroup in KEYNOTE-181. Ann Oncol. (2019) 30:md247–086. doi: 10.1093/annonc/mdz247.086

37. Tabenero R, Van Cutsem E, Bang YJ, Fuchs CS, Wywicz L, Lee KW, et al. Pembrolizumab with or without chemotherapy versus chemotherapy in advanced G/GE adenocarcinoma: the phase 3, KEYNOTE-062 study. J Clin Oncol. (2019) 37:LBA4007. doi: 10.1200/JCO.2019.37.18_suppl.LBA4007

38. Zhang XC, Wang JG, Wang Q, Qu X, Wang B, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. (2019) 10.1038/s41467-019-09762-1

39. Kloosterhof NK, Braat JN, Dubbink HJ, French PJ, Van Den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. (2011) 12:83–91. doi: 10.1016/S1470-2045(10)70053-X

40. Van Lith SA, Molenaar R, Van Noorden CJ, Leenders WP. Tumour immunosuppressive protein CD274 (PD-L1, B7-H1). Front Mol Neurosci. (2018) 11:284–97. doi: 10.3389/fnmol.2018.00082

41. Zeng J, See AP, Phallen J, Jackson CM, Belcadi Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. (2013) 86:227–38. doi: 10.1016/j.ijrobp.2012.12.025

42. Wainwright DA, Kalej DJ, Dietrich J, Clarke JL, Dunn GP, Lim MMH, Cloughesy TT, et al. Phase 2 study to evaluate safety and efficacy of MED4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: an update. J Clin Oncol. (2017) 35:sup2042. doi: 10.1200/JCO.2017.35.15_suppl:sup2042

Hao et al.
66. Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. (2018) 140:317–28. doi: 10.1007/s11060-018-2955-9

67. Suter T, Biollaz G, Gatto D, Bernasconi L, Herren T, Reith W, et al. The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol. (2003) 33:2998–3006. doi: 10.1002/eji.200323611

68. Muldoon LL, Alvarez JJ, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab. (2013) 33:13–21. doi: 10.1038/jcbfm.2012.153

69. Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. (2016) 76:3767–72. doi: 10.1158/0008-5472.CAN-16-0170

70. O’ourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRVIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. (2017) 9:aan984. doi: 10.1126/scitranslmed.aan984

71. Gupta K, Burns TC. Radiation-induced alterations in the recurrent glioblastoma microenvironment: therapeutic implications. Front Oncol. (2018) 8:503. doi: 10.3389/fonc.2018.00503

Conflict of Interest: GC was employed by the company Beijing Qinglian Biotech, Co., Ltd., Beijing, China.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hao, Chen, Zhao, Li, Chen, Zhang, Li, Zhao, Chen, Li and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.